^
NEW:
Evidence
Click below to explore the latest additions to VERI
No biomarker
Prostate Cancer
HLA-A*02:01 positive
Uveal Melanoma
No biomarker
MDS
No biomarker
CMML
IDH1 mutation
Cholangiocarcinoma
HER-2 positive
HER2 Positive Breast Cancer
HER-2 overexpression
Solid Tumor
BRCA1 mutation
Ovarian Cancer
HRD
Ovarian Cancer
BRCA2 mutation
Ovarian Cancer
PD-L1 expression
NSCLC
HLA-A*02:01 positive
Uveal Melanoma
HR positive
HER2 Negative Breast Cancer
FGFR2 rearrangement
Cholangiocarcinoma
FGFR2 fusion
Cholangiocarcinoma
FGFR3 mutation
Urothelial Cancer
FGFR1 rearrangement
CNS Tumor
FGFR2 amplification
Gastric Cancer
FGFR1 rearrangement
Head and Neck Cancer
FGFR2 amplification
Breast Cancer
HER-2 exon 20 mutation
NSCLC
FGFR1 fusion
CNS Tumor
FGFR1 mutation
Urothelial Cancer
FGFR3-TACC3 fusion
Gastric Cancer
BCL2 overexpression
Diffuse Large B Cell Lymphoma
EGFR mutation
NSCLC
EGFR L747P
LUAD
EGFR A767_V769dup
LUAD
EGFR L833V + H835L
LUAD
EGFR T790M + L833V + H835L
LUAD
EGFR T790M + S768I + L858R
LUAD
MYC overexpression
Diffuse Large B Cell Lymphoma
MYC overexpression + BCL2 overexpression
Diffuse Large B Cell Lymphoma
KDR expression
Cervical Cancer
CCL19 overexpression
Follicular Lymphoma
FGFR2-POC1B fusion
Cholangiocarcinoma
FGFR1-TACC1 fusion
GBM
FGFR1-PLAG1 fusion
Head and Neck Cancer
EGFR L833F + L861Q
NSCLC
EGFR L833F + L861Q
NSCLC
PTCH1-GLI1 fusion
Ovarian Cancer
PTCH1-GLI1 fusion
Ovarian Cancer
NF2 mutation
Mesothelioma